Ptc Therapeutics
PTCT
Ptc Therapeutics (PTCT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.92
- EPS estimate
- $0.24
- EPS surprise
- +289.34%
- Revenue surprise
- +20.72%
- Revenue
- $360.5M
- Revenue estimate
- $298.6M
- Reported
- Jul 30, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.24 | $0.92 | +289.34% | $360.5M | SEC |
| Q1 2026 | May 7, 2026 | −$0.47 | −$0.03 | +93.64% | $272.6M | SEC |
| Q4 2025 | Feb 19, 2026 | $0.10 | −$1.67 | −1721.36% | $164.7M | SEC |
| Q3 2025 | Nov 4, 2025 | −$1.13 | $0.20 | +117.65% | $211.0M | SEC |
| Q2 2025 | Aug 7, 2025 | −$1.02 | −$0.83 | +18.74% | $178.9M | SEC |
| Q1 2025 | May 6, 2025 | −$1.01 | $10.04 | +1096.23% | $1.2B | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.54 | −$0.85 | −57.32% | $213.2M | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.52 | −$1.39 | +8.61% | $196.8M | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.12 | −$1.29 | −15.19% | $186.7M | SEC |
| Q1 2024 | Apr 25, 2024 | −$1.27 | −$1.20 | +5.86% | $210.1M | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.14 | −$2.06 | −1390.59% | $307.1M | SEC |
| Q3 2023 | Oct 26, 2023 | −$1.07 | −$1.76 | −65.26% | $196.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.62 | −$2.66 | −64.07% | $213.8M | SEC |
| Q1 2023 | Apr 27, 2023 | −$1.53 | −$1.88 | −22.53% | $220.4M | SEC |
| Q4 2022 | Feb 21, 2023 | −$1.59 | −$2.35 | −48.05% | $167.4M | SEC |
| Q3 2022 | Oct 27, 2022 | −$1.28 | −$1.53 | −19.23% | $217.1M | SEC |
| Q2 2022 | Aug 4, 2022 | −$1.37 | −$2.13 | −55.68% | $165.5M | SEC |
| Q1 2022 | May 3, 2022 | −$1.51 | −$1.78 | −18.05% | $148.7M | SEC |
| Q4 2021 | Feb 22, 2022 | −$1.68 | −$2.03 | −20.89% | $165.2M | SEC |
| Q3 2021 | Oct 28, 2021 | −$1.66 | −$1.89 | −14.08% | $138.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Ptc Therapeutics (PTCT) last report earnings?
Ptc Therapeutics last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did PTCT beat earnings estimates?
Yes. Ptc Therapeutics reported EPS of $0.92 for Q2 2026 against a $0.24 estimate — a 289.34% beat.
How much revenue did PTCT report last quarter?
Ptc Therapeutics reported $360.5M in revenue for Q2 2026, against a consensus estimate of $298.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.